MX2021015333A - Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. - Google Patents
Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.Info
- Publication number
- MX2021015333A MX2021015333A MX2021015333A MX2021015333A MX2021015333A MX 2021015333 A MX2021015333 A MX 2021015333A MX 2021015333 A MX2021015333 A MX 2021015333A MX 2021015333 A MX2021015333 A MX 2021015333A MX 2021015333 A MX2021015333 A MX 2021015333A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- cancer
- treatment
- diseases related
- casein kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
La presente invención se refiere a compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4, tales como distrofias musculares. También se refiere al uso de tales compuestos, o a los métodos de uso de tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19180120 | 2019-06-13 | ||
PCT/EP2020/066280 WO2020249717A1 (en) | 2019-06-13 | 2020-06-12 | Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015333A true MX2021015333A (es) | 2022-03-17 |
Family
ID=66866948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015333A MX2021015333A (es) | 2019-06-13 | 2020-06-12 | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220226340A1 (es) |
EP (1) | EP3982955A1 (es) |
JP (1) | JP2022536149A (es) |
CN (1) | CN114650818A (es) |
AU (1) | AU2020290001A1 (es) |
CA (1) | CA3141279A1 (es) |
IL (1) | IL288924A (es) |
MX (1) | MX2021015333A (es) |
TW (1) | TW202112368A (es) |
WO (1) | WO2020249717A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022127755A1 (en) * | 2020-12-15 | 2022-06-23 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
WO2023241552A1 (en) * | 2022-06-14 | 2023-12-21 | Gritscience Biopharmaceuticals Co., Ltd | Salt and/or crystal form for compounds as casein kinase inhibitors |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
ES2275500T3 (es) | 1999-04-23 | 2007-06-16 | Takeda Pharmaceutical Company Limited | Compuestos de 5-piridil-1,3-azol, procedimiento para su produccion y uso de los mismos. |
CA2426654C (en) | 2000-10-23 | 2010-12-21 | Smithkline Beecham Corporation | 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds |
MXPA03007166A (es) | 2001-02-12 | 2003-11-18 | Hoffmann La Roche | Pirido-pirimidinas 6-sustituidas. |
MXPA04007838A (es) | 2002-02-12 | 2004-10-15 | Smithkline Beecham Corp | Derivados de nicotamida utiles como inhibidores p38. |
RS92004A (en) | 2002-04-23 | 2006-12-15 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
JP4617299B2 (ja) | 2003-03-03 | 2011-01-19 | アレイ バイオファーマ、インコーポレイテッド | p38阻害剤及びその使用法 |
CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
PL1747220T3 (pl) | 2003-12-11 | 2009-09-30 | Aventis Pharma Inc | Podstawione 1H-pirolo[3,2-b, 3,2-c i 2,3-c]pirydyno-2-karboksyamidy oraz pokrewne analogi jako inhibitory kinazy kazeinowej l epsilon |
TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
JP5066516B2 (ja) | 2005-09-01 | 2012-11-07 | アステラス製薬株式会社 | 疼痛の治療に用いられるピリダジノン誘導体 |
FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
PL2493876T3 (pl) | 2009-10-28 | 2014-06-30 | Pfizer | Pochodne imidazolu jako inhibitory kinazy kazeinowej |
LT2654750T (lt) | 2010-12-20 | 2017-05-10 | Pfizer Inc. | Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai |
EP2546357A1 (en) | 2011-07-14 | 2013-01-16 | Erasmus University Medical Center Rotterdam | A new classifier for the molecular classification of multiple myeloma. |
WO2014081923A1 (en) | 2012-11-21 | 2014-05-30 | The Johns Hopkins University | Genomic classifiers for non-invasive identification of high grade prostate cancer with metastatic potential |
ES2489297B1 (es) | 2013-01-22 | 2015-06-10 | Consejo Superior De Investigaciones Científicas (Csic) | Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas |
US9814728B2 (en) | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
EP3102192A2 (en) * | 2014-02-03 | 2016-12-14 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Use of casein kinase i inhibitors for depleting stem cells |
ES2926931T3 (es) | 2014-02-07 | 2022-10-31 | Agency Science Tech & Res | Inhibidores de caseína quinasa 1 basados en azoles 2,4,5-tri-sustituidos como inductores de la cardiomiogénesis |
JP6564406B2 (ja) | 2014-06-19 | 2019-08-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | カゼインキナーゼ1デルタ/イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体 |
LT3691620T (lt) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui |
WO2019103926A1 (en) | 2017-11-21 | 2019-05-31 | Saint Louis University | P38 inhibitors for the treatment of fshd |
US10973820B2 (en) * | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
-
2020
- 2020-06-11 TW TW109119621A patent/TW202112368A/zh unknown
- 2020-06-12 MX MX2021015333A patent/MX2021015333A/es unknown
- 2020-06-12 US US17/617,321 patent/US20220226340A1/en active Pending
- 2020-06-12 EP EP20731871.8A patent/EP3982955A1/en active Pending
- 2020-06-12 WO PCT/EP2020/066280 patent/WO2020249717A1/en unknown
- 2020-06-12 CN CN202080056694.4A patent/CN114650818A/zh active Pending
- 2020-06-12 AU AU2020290001A patent/AU2020290001A1/en active Pending
- 2020-06-12 JP JP2021573234A patent/JP2022536149A/ja active Pending
- 2020-06-12 CA CA3141279A patent/CA3141279A1/en active Pending
-
2021
- 2021-12-12 IL IL288924A patent/IL288924A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3141279A1 (en) | 2020-12-17 |
EP3982955A1 (en) | 2022-04-20 |
CN114650818A (zh) | 2022-06-21 |
TW202112368A (zh) | 2021-04-01 |
WO2020249717A1 (en) | 2020-12-17 |
JP2022536149A (ja) | 2022-08-12 |
US20220226340A1 (en) | 2022-07-21 |
AU2020290001A1 (en) | 2022-01-20 |
IL288924A (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220070A (es) | Inhibidores de parp1 | |
EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
MX2021013661A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos. | |
PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
MX2018008644A (es) | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano. | |
MX2021013602A (es) | Inhibidores de jak. | |
WO2018178243A3 (en) | Dihydrotetrabenazine for use in the treatment a movement disorder | |
MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
NZ745185A (en) | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
MX2021015333A (es) | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. |